ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Failure of CML patients to respond to imatinib therapy has been linked to point mutations in the target protein BCR-ABL and/or AS of the BCR-ABL pre-mRNA (see Section 4.1).